The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence.
- Ignatiadis, Michail
- Abdel Azim, Hatem Hamdy
- Desmedt, Christine
- Veys, Isabelle
- Larsimont, Denis
- Salgado, Roberto
- Lyng, Maria B
- Viale, Giuseppe
- Leyland-Jones, Brian
- Giobbie-Hurder, Anita
- Kammler, Rosita
- Dell'Orto, Patrizia
- Rothé, Françoise
- Laïos, Ioanna
- Ditzel, Henrik J
- Regan, Meredith M
- Piccart-Gebhart, Martine
- Michiels, Stefan
- Sotiriou, Christos
Publication date
February 2016
DOI Publisher
American Medical Association (AMA) ISSN
2374-2437 Citation count (estimate)
12Abstract
The Genomic Grade Index (GGI) was previously developed, evaluated on frozen tissue, and shown to be prognostic in early breast cancer. To test the GGI in formalin-fixed, paraffin-embedded breast cancer tumors, a quantitative reverse transcriptase polymerase chain reaction assay was developed and named the Genomic Grade (GG). The GG assay has the potential to increase the clinical application of the GGI, but robust demonstration of the clinical validity of the GG assay is required.SCOPUS: ar.jinfo:eu-repo/semantics/publishe
Add to ORKG